GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » Asset Turnover

Ra Pharmaceuticals (Ra Pharmaceuticals) Asset Turnover : 0.00 (As of Dec. 2019)


View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Ra Pharmaceuticals's Revenue for the three months ended in Dec. 2019 was $0.00 Mil. Ra Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2019 was $296.55 Mil. Therefore, Ra Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2019 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Ra Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2019 was -52.93%. It is also linked to ROA % through Du Pont Formula. Ra Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2019 was -49.61%.


Ra Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Ra Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals Asset Turnover Chart

Ra Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Asset Turnover
Get a 7-Day Free Trial 0.26 0.07 - 0.02 0.01

Ra Pharmaceuticals Quarterly Data
Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - - 0.01 -

Competitive Comparison of Ra Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Ra Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ra Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ra Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Ra Pharmaceuticals's Asset Turnover falls into.



Ra Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Ra Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2019 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2019 )/( (Total Assets (A: Dec. 2018 )+Total Assets (A: Dec. 2019 ))/ count )
=3/( (219.22+284.152)/ 2 )
=3/251.686
=0.01

Ra Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2019 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2019 )/( (Total Assets (Q: Sep. 2019 )+Total Assets (Q: Dec. 2019 ))/ count )
=0/( (308.938+284.152)/ 2 )
=0/296.545
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Ra Pharmaceuticals  (NAS:RARX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Ra Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2019 is

ROE %**(Q: Dec. 2019 )
=Net Income/Total Stockholders Equity
=-147.108/277.9355
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-147.108 / 0)*(0 / 296.545)*(296.545/ 277.9355)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.067
=ROA %*Equity Multiplier
=-49.61 %*1.067
=-52.93 %

Note: The Net Income data used here is four times the quarterly (Dec. 2019) net income data. The Revenue data used here is four times the quarterly (Dec. 2019) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Ra Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2019 is

ROA %(Q: Dec. 2019 )
=Net Income/Total Assets
=-147.108/296.545
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-147.108 / 0)*(0 / 296.545)
=Net Margin %*Asset Turnover
= %*0
=-49.61 %

Note: The Net Income data used here is four times the quarterly (Dec. 2019) net income data. The Revenue data used here is four times the quarterly (Dec. 2019) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Ra Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
87 Cambridge Park Drive, Cambridge, MA, USA, 02140
Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.
Executives
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco director, officer: President and CEO 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins 10 percent owner
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner officer: Executive VP and CFO C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

Ra Pharmaceuticals (Ra Pharmaceuticals) Headlines

From GuruFocus

4 Stocks With More Than 20% Price Increases on Thursday

By James Li James Li 10-10-2019